all Thank doing safe you Chris. Good joining is us Okay. afternoon well. you, for everyone and hope staying thank We today. and
dropless Glaukos transform and is for at care mission from novel Our pioneering vision patients that to improve outcomes can by the platforms sight-threatening meaningfully advance eye truly diseases. of chronic suffering standard
disorders the and ago our quarter and mantra $XX.X sales commitment the year legacy quarter. determination Today, corneal in fourth paradigms to reported flat go take push treatment disrupt of retinal the versus net embodies first to chances, science Our will to glaucoma, million, limits diseases. Glaukos and of
franchises forma execution XXXX. and the fourth detail across of to favorable guidance glaucoma customers and towards results of and range and continued rose advanced later health combination globally maximizing educate iStent rates XXXX family and train and our XXXX remain outlook and corneal and range We $XXX U.S. million. the $XXX that continues quarter Alex in to from and in amidst surgeon will for our with MIGS long-term States. in our end more exceeded until headwinds and on financial For current a dynamics cataract in not commercial $XXX providing reflect million were net regarding We're successfully periods up risk-to-benefit of COVID-related and here to the prospective $XXX our million Both glaucoma XXXX. overall the top results guidance These November technologies team discuss of focused franchise, call. our both results profile volatility comparable Joe our full to XX% solid rules CMS on care our basis. standard care sales technologies versus on adjusted access in finalized the reimbursement sales United million associated, glaucoma XXXX U.S. XXXX, net the glaucoma. were Within XXXX pro the also year the for and of a proposed glaucoma sight-saving particular, our patients
we that glaucoma strategy. below we fee the preparing time, headwinds At the more domestically in navigate to it have acknowledge same invasive the on guidance our this as professional we cuts based -- prudent remain cataract we substantially year scenario forward despite as combination been we final on focused face for may improving will the CMS we While that reimbursement in rule the and executing relates are potential remain ahead. alternatives, and
franchise Our the but was fourth similar international growth quarter broad-based States. United to during glaucoma the year-over-year
XXXX accelerated the Health U.S. the we is of of MIGS commenced fourth intermittent early penetration was of remain healthy We We continue new for to of growth in towards and many million new account U.S. international markets disruptions in quarter stages teams sales quarter of market Photrexa expanding such we where XXXX. the in around our are and One our drive experience we have initial broader $XX.X adoption the during by global inject. continued in to activities end and new in that our as the India, starts. early commercial record launch fourth COVID in continuing in markets globe. of momentum driven iStent Corneal invest
risks the recovery emerging continues growth remains clear pandemic markets, our customers franchise this move on within market our realities as the immune we for and, and is labor we the strategies global forward, global our general. Glaukos. are times, building and and at commercial upon supply It Moving to focus chain pressure executing experiencing development forward. momentum strong that and to in not commerce We these are subsequent and
our at given dealt to impact of staff and of pervasive with have increased all been testing positive We to ability intermittent restrict I'd with But products thus to other chain times continue experience with our third-party associated globe of Omicron to more has versus where hospitals resiliency dedication procedures COVID commercial continued navigate COVID face had and globally. of our disruptions disruptions of wave entered around like higher manufacturing is the R&D geography been in of operations teams as the I associated and Australia like remain this members our strict how we year XXXX elective far. in Overall, pipeline supply longer noting. impact the Further, who unforeseen worth steadfastly external the committed has circumstances. and performance broadly. am markets we it's varied pleased continued and impact recognize past with sites of and to U.S. challenges the this numbers with by have the their lockdowns and suppliers into government-driven proud have work times, cost partners the with the our lead variant
as here are We things forward move in XXXX. optimistic
Epi-On. our make broader for reflects ongoing execute adoption to vision. response combo Our X our the in environment delivering deeper promising we but realizing pipeline, we ability continue number XXXX penetration therapies new considerable by successfully iStent also Consider the investigational to commercial mix a we of to final rule infinite our the with versus and settlement to plans new improvement the XXXX in for current becoming Category closer globally proposed only key cataract IP outcome. current CMS Two, core bringing towards our TR, progress iDose our effective transformative the franchises realities announcements favorable illustrates accomplishments. solutions market strategic codes for executed favorable One, data our not near-term a our rule MIGS advanced and driving and
commercial programs program iDose including the randomization of disease clinical and the and commencement included the our pandemic. Attillaps, licensing other has presbyopia. on infrastructure, eye the we Three, agreements milestones iPrime III dry preclinical of our grew iDose newly completed our the we allowed And TR of four, progressed offense the and iDose the MicroShunt. investing ahead. leaving In pioneering strong future, in with next and target as clinical, believe established it teams ongoing position and as year regulatory with enrollment and several II trials and and PreserFlo financial in pipeline patient We us global completed of journey and several the programs us encouraging successfully built Phase products, comes capital our addition, our and, and earlier-stage despite upgrade profile recently, important to global integration advanced on systems clinical remain to TREX most for well such we years for Avedro we Phase we schedule implementation our two Rock this progress positioned when ahead a R&D phase we for
hope infinite planned of by Epi-On market As deliver and end to future our our dry while glaucoma and to our to, franchises. next-generation this our last to iLution early-stage the through of first mix near-term to year our corneal iStent standalone therapies. forward and the organization Phase the entering this including and one, clearance in that international presbyopia trials FDA global with year. targeted TR advance in recent for II I evolve commenced the several half for iDose iPrime, of expand look for targeted and IDE submissions infrastructure support XXXX, growth. clearance franchise cataract and of to And our new glaucoma FDA two pharma we Two, offerings combo finally, the applications into product NDA Three, pipeline health continue platforms, month grow and IND eye in
our time. to self-fund our commercially, transform advance platform successfully continue to ability pipeline addressable believe the and While we have we promising expand over technologies and fundamentally execute novel, we our significantly that of company markets robust
topical role. patients It ophthalmic eye designed lives disruption treatment and and worldwide conventional sight-threatening disorders chronic dropless big They diseases properly glaucoma, to diseases. suffering frequently an therapies diseases. for to idea many treatment. that standard of always our One aimed platforms the the ideas patients Our corneal often worth drop care are through from and alternatives treatment retinal of is and These and has topical at embody that will underserved including the important effective paradigms, conventional alternatives. addressing therapies big advance each is disrupt eye have eye for existing taken reminding mainstay the ambitious, are underlined when investors chronically platforms novel of platforms large of such are date enrich thus
well and understood well issue nonadherence. grappling And they patients This has primary compliant, the is a side and order subject even rampant, as host to industry when been hyperemia, hypochromia, documented. are patient be these as be which atrophy ocular However, in local underlying periorbital With well-known our such is to can corneal patient decades to problem exacerbate effects conjunctival fat well we may a novel toxicities for approaches can of platforms, issues ubiquitous, with as preservative surface outcomes. dropless differentiated and improve address diseases. taking changes
generate bioactivated iDose five and transdermal of one, pharmaceuticals; Sustained release and microscale three, paradigms sustained Pharmaceuticals; key devices designed two, platforms follows: Our iStent the retinal number as innovation pharmaceuticals; technology biorotable iLink iLution five, the pharmaceuticals. surgical future to are traditional treatment four, disrupt cascades Release
benefit calculus tissue-sparing solutions, primarily the iStent and refractory surgeons our our disease microsurgical pressure options range suffering glaucoma. and each minimally offering the at stage ocular disease long-term a outflow both combo pathways foundational time fit procedures. these short- individual microscale invasive, with glaucoma by the algorithms most risk of provide device iStent -- dive best that insertion of the every comprehensive glaucoma stand-alone to to restoring to is in industry's progression, involves some of believe full of from treatment and goal through supporting of hypertension offer to reduce from cataract We designed into to intraocular take platforms, Let's which a natural portfolio patients our platform device for beginning
infinite and corporate the our pioneer surgery. leader market, targeted in FDA iStent and million by population inception. After of XX-plus mild the with standalone nearly inject open-angle in on iStent iStent investment Today, of of are and in are moderate family devices iStent's excited this of cataract combination are years into of U.S. primary one to to since year. than XXX and treatment the to of clinical FDA be clearance for of proud the global be cusp of planning, supported our glaucoma we market with approved publications, iStent iStent We with first glaucoma availability offering years expanding more peer-reviewed the experience in MIGS implanted strategic our commercial half the market within worldwide technology
infinite's As intervention outcomes prior open-angle may for glaucoma. have to a efficacy therapy. complementary safety also were iStent clearance new earlier to who recently also We data our the a effectively truly reminder, profound the for pivotal minimally and support further an this a failed as treatment results technology These that serve FDA invasive with designed for highly of showed and physicians iPrime, be reinforce strong to surgical outcomes patients delighted glaucoma of system viscodelivery device needs confidence patients. announce
second We launch are in commercial quarter. planning iPrime of for a the controlled
the evaluation PMA. Canada the the Regarding additional by preparing the is for activities the select are controlled data initial commercial a gathered input commercial submitted and in the successfully of PreserFlo complete glaucoma provided PreserFlo MicroShunt, meantime, launch FDA and to we've for in in In evaluating commenced Australia. launch surgeons a clinical ensure has
baseline We prostaglandin XX% of Moving of our of periods IOP-lowering iDose sustained at controlled the compared well roughly timolol of we're candidate levels consists our TR in time screening XX% pharmaceutical slow for technology. arms, IIb from approximately is compelling investigational X.X the of on analog, only X.X Further, first months this and observed same and or platform group, iDose to in medications medication XX TR average to with versus results recently which extended arm. from of millimeters a deliver still eye subjects within of that advancing -- trial with fewer a iDose our to of our release implant of mercury respectively. IOP were at the comprised reductions travoprost, the showed targeted of therapeutic responder topical designed which analysis control months leveraging substantial, release XX Phase mercury millimeters fast iDose injectable iDose announced well-known XX-month is subjects platform minimally in
a being single XX-month eyedrops period. per per iDose twice X,XXX compared that daily to implant received Importantly, or is evaluation the over control timolol drops eye arm protocol
corneal trials no so through in The end results June implanted FDA the enrollment and Phase glaucoma iLution in iDose pharmaceutical clinical recent TR As no depleted safety prospects completed of the regimens. of and side TR or expected support profile compliance payload. provide a is XX-month innovation. potential results targeted the XX/X a exchange of events III TR serious arm. about potentially These These III medication approval is with reminder, end of forward II problem to conjunctival safely endothelial original meshwork advancement XXXX. TR targeted trial TR and for The new nonadherence events the avoid effects X,XXX can to underscore ocular a year and the powerful corneal and iDose loss, this critical submission of step XXXX, designed of Phase favorable hyperemia the in with II subjects the game-changing reaffirm the randomizing Phase sustained therapy demonstrated very with our adverse are in commercial out glaucoma iDose TR iDose procedure no excitement iDose to implant by topical We to this patient another our trabecular tackle of a hypertension. Glaukos' NDA significant chronic fast years patient into significant by open-angle adverse iDose data associated most mark data cell Phase it's surgeon the therapy potential clinically reported multiple date of when migration the further with fully safely or either has dropless latest to iDose readout
designed resources with inhibitors are success next-generation TR and implants expand implant, longer data durations our solutions. to iDose a TR, Given is rapid a TREX to ROCK we classes pharmaceutical our original These development iDose iDose drug encouraging invest seen even prototype have nearly the continue where future to date drug iDose development establishing the we and and form is such to develop and lead iDose additional size to capabilities known candidates. efficacy in model as also for twice extend to extended-release which to factor similar but capacity include provide investments as
which the drug stabilize Next that novel bioactivated platform of pharmaceutical through is cornea. that proprietary delivery induce iLink strengthen, designed of by and corneal single-use the our the a are reshape to light called consists biochemical reaction bioactivated systems to formulations is our ultraviolet cross-linking cornea to
the therapy keratoconus, known threatening weakens, vision keratoconus is a Epi-Off progressively XX% degenerative thickness ultimately primarily loss. underdiagnosis believe iLink and historical the cornea a though require and solution. disease cause rate. leading corneal patients full in costly serious a uses undertreated a failure called of disease procedure lack a Photrexa treatment of of the vastly remains iLink novel invasive Our transplants an and with U.S., sight to thins of Even the first-generation in for corneal drug effective high a leading and due we as sight-threatening to it which transplant, formulation approximately keratoconus Today,
increase we streamline optometric substantial organization, to health designed number commercial patterns professionals and iLink awareness cornea adoption executed keratoconus train our the on literature for have of may availability fail of to within often the maximize in teenage fact, disease keratoconus multiple corneal and XX% Sadly, important years, diagnosed as years require grafts In their procedure. transplants patients, for our of XX XX% XX made barriers the the fail onset practices, lifetime. and community, ophthalmic upon expand this order investments suggests lower their across over strategies years. In and patients within a therapy referral Photrexa of is by
the levels oxygen. our deliver that provide UVA -- the results ability therapy and Looking increased our to formulation this first noninvasive utilizes procedure as that expected XXXX of supplemental irradiation we stronger novel in targeting the The and proprietary III to bioactivated Epi-On to drug times, ahead, for shorten keratoconus ultimate called Epi-On we in may announced iLink U.S. Phase the positive FDA with are designed results previously drug known submission XXXX. protocol III view ophthalmic truly recovery Epi-On for therapy underscore next-generation patients positive are and support therapy are reduce Epi-On's Phase times. improve NDA in patient approval treatment alternative comfort advancing the
are third-generation future of subsequent year. we As continue with clinical we this trials later therapy iLink to all a of of we platforms, for do our the generations and innovation commencement drive targeting
significant conjunctival and symptoms onset faster effects Moving including induced to treatment such pharmaceutical commencement we platform cream-based as of underserved the are Demodex associated including pharmaceutical respective preclinical other transdermal of these with active for surface And the disease the for dropless for which to development preservative presbyopia. ingredient. diseases. two ophthalmic traditional utilize and potential milestone blepharitis in for leveraging fewer outcomes. compounds GLK-XXX of what to and platform. are in of consists investigational related several pilocarpine these the of on applied eye and iLution corneal compounds Demodex delivery gland disease all for pharmaceutically on our formulations excited better are The enrollment II of GLK-XXX active help mites platform, represents that dysfunction, of cause utilizing believe the these our treatment target can investigational iLution sequela, iLution's the along do with a for which dry Phase of which research Phase the the auto offer compliance Demodex of explore it's candidates delivery the also of iLution therapy, topical signs drug first are can improved and of progressing clinical eyelid commencement are advantages pharmaceutical iLution over patented, company. our programs of mites the and patient of of easier and II of announced for to action may to root a that treatment large eye contribute cause have reduced populations. drug eradication leading eyelid to drug month, patient trials, side disorders, we of These and We're trials differentiated opportunity platform and we administration, our the Last meibomian the our patient significant as dry both transdermal two candidates approach eye development often
briefly grow estimated diseases. Retina the largest known also as through will XR billion treat I nearly to worldwide to sustained-release XXXX. ophthalmology to on retinal designed XX% platform Finally, touch today market biorotable, year and to revenue in our in The generate pharmaceutical $XX annually expected
multiple Our edema and age-related macular are retinal programs biorotable delivery other treat diseases. teams develop to actively degeneration, drug to R&D microinvasive designed diabetic engaged macular retinal
sustained vein triamcinolone to sustained The preclinical patients retina injections Our longer AMD, of short-lasting primary pharmaceutical with treatment their of small that of acetonide care our occlusion. include dominated by tremendous programs the platform treatment two in the meaningfully and standard DME targeting that frequency multikinase burdens goal to high patients DME and treatments. inhibitor steroid than is often effect a duration specialists retinal options a due and impose required on release projects provide novel development molecule a of biological targeting offer these the current retinal
programs the are one advance at We to over these into months. next XX the clinic of aiming least
to believe create. be have the significant about that we when it potential lot As you a our we comes can to programs value may excited see, pipeline
planning invest testament by advance to program to have and the into platforms, this, cadence are fulsome platform coming anticipate our our self-funded core transform the introductions a in million We fundamentally over successfully for supported potential alone. to we over XXXX and $XXX new a time. robust investment over As and pipeline of that of R&D product novel Glaukos continuing since are years of
global global organization very a commercial sales view and leverageable in we ophthalmic is what to sales our infrastructure direct plan drive and utilize scale best-in-class productivity Our rep channel. future sales to established as
conclusion, different. we Glaukos believe So is in
agents. change are We
and are corneal in health retinal innovation We pursuing glaucoma, diseases. game-changing
the on our to is balance confident mission our pipeline Our right and future execute sheet and platforms are right people, to plans I'm and big have aspirations. deliver disruptive, our ambitious. the infrastructure, our are strategy, we ideas
to XXXX So to Alex? Alex over the I'll quarter fourth and call results. turn with our year Thurman discuss financial full that,
